All In Biotech

Drug Trial Radar · NCT04691804

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 496 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

496

Actual

Start

Mar 18, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).

Conditions

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

  • Fuzuloparib , Abiraterone acetate and PrednisoneDrug

    1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po 2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po 3. Prednisone tablets (strength: 5 mg) 5mg, Bid po

  • Fuzuloparib Placebo, Abiraterone acetate and PrednisoneDrug

    1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po 2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po 3. Prednisone tablets (strength: 5 mg)5mg, Bid po

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rPFS by blinded independent central review (BICR) using RESIST1.1 and PCWG3Time frame: up to 3 years

Locations

147 sites in 13 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Urological Associates of Southern Arizona PC

    Tucson, Arizona

  • Desert Hematology Oncology Medical Group Inc

    Rancho Mirage, California

  • San Bernardino Urological Associates Medical Group

    San Bernardino, California

  • UF College of Medicine - Jacksonville

    Jacksonville, Florida

  • Hematology Oncology Clinic

    Baton Rouge, Louisiana

  • VA Maryland Health Care System

    Baltimore, Maryland

  • Johns Hopkins

    Baltimore, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • GU Research Network LLC

    Omaha, Nebraska

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Weill Cornell Medicine

    New York, New York

  • Messino Cancer Centers

    Asheville, North Carolina

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Carolina Urologic Research Center, LLC

    Myrtle Beach, South Carolina

  • Tennessee Oncology

    Chattanooga, Tennessee

  • Center for Onology and Blood Disorders

    Houston, Texas

  • Bendigo Health

    Bendigo, Australia

  • Concord Repatriation General Hospital

    Concord, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • Gosford Hospital

    Gosford, Australia

  • Ashford Cancer Centre Research

    Kurralta Park, Australia

  • The Alfred Hospital

    Melbourne, Australia

  • Western Health

    St Albans, Australia

  • Macquarie University

    Sydney, Australia

  • Riverina Cancer Care Centre

    Wagga Wagga, Australia

  • Sydney Adventist Hospital

    Wahroonga, Australia

  • UZ Gent

    Ghent, Belgium

  • Centre Hospitalier de Jolimont

    Haine-Saint-Paul, Belgium

  • AZ Groeninge

    Kortrijk, Belgium

  • Beijing cancer hospital

    Beijing, China

  • Beijing Friendship Hospital

    Beijing, China

  • Beijing Hospital

    Beijing, China

  • Cancer hospital Chinese academy of medical science

    Beijing, China

  • Hunan Cancer Hospital

    Changsha, China

  • XiangYa hospital central south university

    Changsha, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • Chongqing Cancer Hospital

    Chongqing, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.